Enhanced sensitivity of dopaminergic neurons to rotenone-induced toxicity with aging.

[1]  P. Jenner.  Parkinson's disease, pesticides and mitochondrial dysfunction , 2001, Trends in Neurosciences.

[2]  E. Richfield,et al.  Age‐related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype , 2003, The European journal of neuroscience.

[3]  Diana Brahams,et al.  Medicine and the Law , 1983, The Lancet.

[4]  Y. Kagawa,et al.  Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. , 1989, Biochemical and biophysical research communications.

[5]  A. Mooradian.  Effect of aging on the blood-brain barrier , 1988, Neurobiology of Aging.

[6]  H. Chapel,et al.  CLINICAL RELEVANCE OF SPECIFIC IgG ANTIBODIES TO CARDIOLIPIN , 1989, The Lancet.

[7]  Andreas Schober,et al.  Classic toxin-induced animal models of Parkinson’s disease: 6-OHDA and MPTP , 2004, Cell and Tissue Research.

[8]  M. L. Genova,et al.  Decrease of rotenone inhibition is a sensitive parameter of complex I damage in brain non‐synaptic mitochondria of aged rats , 1997, FEBS letters.

[9]  H. Checkoway,et al.  Epidemiologic approaches to the study of Parkinson's disease etiology. , 1999, Epidemiology.

[10]  J. C. Stoof,et al.  Effects of chronic activation of dopamine D-2 receptors in cultures of rat fetal dopaminergic neurons: indications for alterations in functional activity. , 1995, Brain research. Developmental brain research.

[11]  I. Date,et al.  Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis , 1990, Brain Research.

[12]  MK‐801 alters the effects of priming with L‐DOPA on dopamine D1 receptor‐induced changes in neuropeptide mRNA levels in the rat striatal output neurons , 2002, Synapse.

[13]  Ken-ichi Isobe,et al.  An inhibitor of mitochondrial complex I, rotenone, inactivates proteasome by oxidative modification and induces aggregation of oxidized proteins in SH‐SY5Y cells , 2003, Journal of neuroscience research.

[14]  W. Tatton,et al.  Interactions Between MPTP-Induced and Age-Related Neuronal Death in a Murine Model of Parkinson’s Disease , 1992, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[15]  J. Langston,et al.  Older dopaminergic neurons do not recover from the effects of MPTP , 1987, Neuropharmacology.

[16]  Cheryl D. DiCarlo,et al.  Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone , 2004, Experimental Neurology.

[17]  A. H. V. Schapira,et al.  MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.

[18]  T. Berger,et al.  Effects of intraventricular 6-hydroxydopamine on the dopaminergic innervation of striatum: Histochemical and neurochemical analysis , 1986, Brain Research.

[19]  C. Hertzman,et al.  A case‐control study of Parkinson's disease in a horticultural region of British Columbia , 1994, Movement disorders : official journal of the Movement Disorder Society.

[20]  Todd B. Sherer,et al.  Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.

[21]  J. Langston,et al.  Aetiology of Parkinsońs disease , 1983 .

[22]  E. Love,et al.  Parkinson's disease and exposure to agricultural work and pesticide chemicals , 1992, Neurology.

[23]  W. Cass,et al.  Enhanced effects of 6-hydroxydopamine on evoked overflow of striatal dopamine in aged rats , 2002, Brain Research.

[24]  Andreas Hald,et al.  Oxidative stress and inflammation in Parkinson's disease: is there a causal link? , 2005, Experimental Neurology.

[25]  J. Gorell,et al.  Multiple risk factors for Parkinson's disease , 2004, Journal of the Neurological Sciences.

[26]  Y. Agid,et al.  Dopaminergic sprouting in the rat striatum after partial lesion of the substantia nigra , 1996, Brain Research.

[27]  M. Laakso,et al.  Reactive microglia in aging and dementia: an immunohistochemical study of postmortem human brain tissue , 1999, Acta Neuropathologica.

[28]  L. Felzien,et al.  Increased chemokine gene expression during aging in the murine brain , 2001, Brain Research.

[29]  A. Mclean,et al.  Age-Environment and Gene-Environment Interactions in the Pathogenesis of Parkinson's Disease , 2002, Reviews on environmental health.

[30]  H. Gundersen,et al.  Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator , 1991, The Anatomical record.

[31]  B. Ritz,et al.  Parkinson's disease mortality and pesticide exposure in California 1984-1994. , 2000, International journal of epidemiology.

[32]  M. Esposti.  Inhibitors of NADH-ubiquinone reductase: an overview. , 1998 .

[33]  Todd B. Sherer,et al.  Subcutaneous Rotenone Exposure Causes Highly Selective Dopaminergic Degeneration and α-Synuclein Aggregation , 2003, Experimental Neurology.

[34]  W. Dauer,et al.  Parkinson's Disease Mechanisms and Models , 2003, Neuron.

[35]  M. Chesselet,et al.  Variable effects of chronic subcutaneous administration of rotenone on striatal histology , 2004, The Journal of comparative neurology.

[36]  I. Date,et al.  MPTP-treated young mice but not aging mice show partial recovery of the nigrostriatal dopaminergic system by stereotaxic injection of acidic fibroblast growth factor (aFGF) , 1990, Brain Research.

[37]  D. Yurek,et al.  Lesion-Induced Increase of BDNF Is Greater in the Striatum of Young versus Old Rat Brain , 2000, Experimental Neurology.

[38]  S. Barros,et al.  Aging and oxidative stress. , 2004, Molecular aspects of medicine.

[39]  E. Bézard,et al.  Adaptive changes in the nigrostriatal pathway in response to increased 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced neurodegeneration in the mouse , 2000, The European journal of neuroscience.

[40]  T. Sherer,et al.  The rotenone model of Parkinson's disease: genes, environment and mitochondria. , 2003, Parkinsonism & related disorders.

[41]  I. Date,et al.  Limited recovery of striatal dopaminergic fibers by adrenal medullary grafts in MPTP-treated aging mice , 1990, Experimental Neurology.

[42]  B. Liu,et al.  Synergistic Dopaminergic Neurotoxicity of the Pesticide Rotenone and Inflammogen Lipopolysaccharide: Relevance to the Etiology of Parkinson's Disease , 2003, The Journal of Neuroscience.

[43]  A. Kelley,et al.  Effects of selective dopamine D1 or D2 receptor blockade within nucleus accumbens subregions on ingestive behavior and associated motor activity , 2002, Behavioural Brain Research.

[44]  D. Calne,et al.  AETIOLOGY OF PARKINSON'S DISEASE , 1983, The Lancet.

[45]  Jean Féger,et al.  Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats , 2003, Journal of neurochemistry.

[46]  J. Schulz,et al.  Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra , 1997, Brain Research.

[47]  Nicolas Lapointe,et al.  Rotenone induces non‐specific central nervous system and systemic toxicity , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[48]  A. Ghelli,et al.  Inhibitor sensitivity of respiratory complex I in human platelets: A possible biomarker of ageing , 1996, FEBS letters.

[49]  M. Schwartz.  Macrophages and Microglia in Central Nervous System Injury: Are They Helpful or Harmful? , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[50]  D. Yurek,et al.  Differential expression of GDNF, BDNF, and NT-3 in the aging nigrostriatal system following a neurotoxic lesion , 2001, Brain Research.

[51]  A. Barbeau.  Etiology of Parkinson’s Disease: A Research Strategy , 1984, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[52]  Todd B. Sherer,et al.  Mechanism of Toxicity in Rotenone Models of Parkinson's Disease , 2003, The Journal of Neuroscience.

[53]  C. C. Johnson,et al.  The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living , 1998, Neurology.

[54]  B. Volpe,et al.  Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice , 2003, Brain Research.

[55]  M. Horne,et al.  Axonal sprouting following lesions of the rat substantia nigra , 2000, Neuroscience.

[56]  C. Finch,et al.  Glial gene expression during aging in rat striatum and in long‐term responses to 6‐OHDA lesions , 1999, Synapse.

[57]  C. Finch,et al.  Aging and Increased Hypothalamic Glial Fibrillary Acid Protein (GFAP) mRNA in F344 Female Rats , 2002, Neuroendocrinology.

[58]  P. R. Hof,et al.  An improved thioflavine S method for staining neurofibrillary tangles and senile plaques in Alzheimer's disease , 1992, Experientia.

[59]  Todd B. Sherer,et al.  An In Vitro Model of Parkinson's Disease: Linking Mitochondrial Impairment to Altered α-Synuclein Metabolism and Oxidative Damage , 2002, The Journal of Neuroscience.

[60]  D. Joel,et al.  The connections of the dopaminergic system with the striatum in rats and primates: an analysis with respect to the functional and compartmental organization of the striatum , 2000, Neuroscience.

[61]  C. Marsden,et al.  Mitochondrial Complex I Deficiency in Parkinson's Disease , 1990, Lancet.

[62]  B. Liu,et al.  Distinct Role for Microglia in Rotenone-Induced Degeneration of Dopaminergic Neurons , 2002, The Journal of Neuroscience.

[63]  Mark J. West,et al.  New stereological methods for counting neurons , 1993, Neurobiology of Aging.

[64]  H. Gundersen,et al.  The efficiency of systematic sampling in stereology — reconsidered , 1999, Journal of microscopy.

[65]  D. Sparks,et al.  Dystrophic microglia in the aging human brain , 2004, Glia.

[66]  D. L. Le Couteur,et al.  Age-related alteration in hepatic disposition of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and pesticides. , 2002, Pharmacology & toxicology.

[67]  W. Schmidt,et al.  Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats , 2002, Behavioural Brain Research.

[68]  J. C. Stoof,et al.  Repeated administration of a selective dopamine D2 receptor agonist to 6-OHDA — lesioned rats does not affect the survival and outgrowth of intrastriatal fetal mesencephalic grafts , 2004, Experimental Brain Research.

[69]  T. Peng,et al.  Mitochondrial dysfunction in Parkinson's disease. , 1999, Biochemical Society symposium.

[70]  J. Langston,et al.  MPTP and aging. Studies in the C57BL/6 mouse. , 1993, Advances in neurology.

[71]  Bin Liu,et al.  Critical Role for Microglial NADPH Oxidase in Rotenone-Induced Degeneration of Dopaminergic Neurons , 2003, The Journal of Neuroscience.

[72]  D. Linnemann,et al.  Regional changes in expression of NCAM, GFAP, and S100 in aging rat brain , 1994, Neurobiology of Aging.

[73]  E. Love,et al.  An assessment of the usefulness of demographic data provided by surrogate respondents in a case-control study of Parkinson's disease. , 1992, Journal of clinical epidemiology.

[74]  J. Langston,et al.  The relationships between aging, monoamine oxidase, striatal dopamine and the effects of MPTP in C57BL/6 mice: a critical reassessment , 1992, Brain Research.

[75]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .

[76]  R. Swerdlow,et al.  Origin and functional consequences of the complex I defect in Parkinson's disease , 1996, Annals of neurology.

[77]  M. Vila,et al.  The rotenone model of Parkinson's disease , 2003, Trends in Neurosciences.

[78]  T. Morgan,et al.  Age-Related Activation of Microglia and Astrocytes: In Vitro Studies Show Persistent Phenotypes of Aging, Increased Proliferation, and Resistance to Down-Regulation , 1998, Neurobiology of Aging.

[79]  Y. Agid,et al.  Long‐Term Induction of Tyrosine Hydroxylase Expression: Compensatory Response to Partial Degeneration of the Dopaminergic Nigrostriatal System in the Rat Brain , 1995, Journal of neurochemistry.